ASSERTIO THERAPEUTICS, INC. ASRT Income Statement

Assertio therapeutics, inc. (ASRT)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenues:
Total revenues
20,917	59,225	55,147	57,203	57,929	42,599	77,493	63,274	128,404	94,407	95,413	100,457	90,447	123,911	110,524	116,682	104,780	111,172	104,856	94,504	32,203	194,602	51,485	67,732	76,544	40,608	37,460	29,963	26,174	26,589	33,282	14,110	16,835	12,132	16,522	21,218	83,101	20,127	24,419
License and other revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,235	760	5,760	11,760	3,312	5,760	760	2,964	764	11,397	1,332	5,305	4,037	5,138	4,998	67,625	10,223	12,671
Non-cash PDL royalty revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	146,956	19,771	33,297	42,784	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and expenses:
Cost of sales (excluding amortization of intangible assets)
1,399	-	-	-	2,575	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of sales (excluding amortization of intangible assets)
-	-	2,243	2,124	-	704	2,975	2,753	12,044	17,703	17,396	19,725	17,774	22,657	20,243	20,965	23,549	21,007	20,914	22,865	3,112	3,246	3,523	4,675	3,702	2,168	1,751	1,688	1,484	2,316	1,763	1,442	518	619	1,150	2,140	1,635	2,499	2,981
Research and development expenses
1,041	-	-	-	1,793	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development expenses
-	-	1,476	1,263	-	-	2,127	2,180	1,528	-	1,761	5,614	5,084	9,154	10,412	7,116	5,949	6,340	4,629	4,714	1,858	2,033	1,644	1,397	2,042	2,024	1,339	1,412	3,298	3,185	5,270	3,525	3,482	2,782	3,208	4,043	5,154	4,602	4,570
Promotion fee expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	6,023	11,055	10,262	6,791	8,099
Other selling, general and administrative expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,537	15,451	9,976	7,241	4,313	4,541
Selling, general and administrative expenses
27,314	22,949	36,117	24,755	25,045	25,468	33,409	31,308	29,033	48,317	48,850	50,010	48,519	48,462	51,574	51,903	52,559	58,337	49,065	57,408	34,542	28,958	27,078	32,573	32,517	27,471	26,374	25,368	25,963	24,020	26,832	25,021	21,773	21,536	21,474	21,031	17,503	11,104	12,640
Amortization of intangible assets
7,800	25,487	25,444	25,443	25,400	25,443	25,443	25,444	25,444	25,541	25,734	25,735	25,735	25,734	27,037	27,037	27,037	27,060	27,013	26,731	2,540	2,540	2,540	2,542	2,539	1,465	1,158	963	962	-	958	105	-	-	-	-	-	-	-
Restructuring Charges
-	-	0	0	-	1,859	3,911	5,814	9,017	-	434	3,441	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on settlement agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	40,000	0	0
Total costs and expenses
37,549	250,210	65,280	53,585	54,857	55,681	67,865	67,499	77,066	127,092	94,175	104,525	97,112	106,007	109,266	107,021	109,094	137,744	101,621	111,718	42,052	36,777	34,785	41,187	40,800	33,128	30,622	29,431	31,707	30,480	34,823	30,093	25,773	24,937	25,832	27,214	-15,708	18,205	20,191
(Loss) income from operations
-16,632	-190,985	-10,133	3,618	3,072	-13,082	9,628	-4,225	51,338	-32,685	1,238	-4,068	-6,665	17,904	1,258	9,661	-4,314	-26,572	3,235	-17,214	-9,849	157,825	16,700	26,545	35,744	7,480	6,838	532	-5,533	-3,891	-1,541	-15,983	-8,938	-12,805	-9,310	-5,996	98,809	1,922	4,228
Other income (expense):
Interest and other income
-	-	-	-	-	-	-	-	-	-	72	282	250	175	113	67	130	419	62	61	57	145	23	20	27	519	27	46	70	77	96	204	143	-289	410	357	79	100	56
Gain (Loss) on Extinguishment of Debt
-31,608	-	26,385	-	0	-	0	-	-	-	0	-5,364	-	-	-	-5,777	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense
8,674	13,121	13,872	14,842	16,554	16,613	17,190	17,010	18,068	17,855	17,815	17,758	20,124	20,537	20,307	20,148	22,727	22,702	22,634	22,078	6,022	6,123	1,910	616	626	470	285	40	116	-	39	-	-	1	24	39	69	130	157
Loss on prepayment of Senior Notes
8,233	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Litigation settlement
-	-	0	-	-	-	62,000	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-3,325	6,561	-764	-1,240	-609	224	677	67	229	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense on PDL liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	4,364	4,903	5,379	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income (expense)
59,910	-	11,749	-	-17,163	-	45,487	-	-	-1,288	-17,743	-22,840	-19,874	-	-20,194	-25,858	-22,597	-22,283	-22,572	-22,017	-5,965	-5,978	-6,251	-5,499	-5,978	-4,439	-258	6	-46	77	57	204	143	-290	386	318	10	-30	-101
Net income (loss) before income taxes
43,278	-197,545	1,616	-12,464	-14,091	-29,471	55,115	-21,168	33,499	-33,973	-16,505	-26,908	-26,539	-2,458	-18,936	-16,197	-26,911	-48,855	-19,337	-39,231	-15,814	151,847	10,449	21,046	29,766	3,041	6,580	538	-5,579	-3,814	-1,484	-15,779	-8,795	-13,095	-8,924	-5,678	98,819	1,892	4,127
Income tax expense
2,000	-4,909	-1,715	1,141	200	-5,300	6,845	-120	-325	-869	-513	-249	202	41,892	-6,042	-5,656	-5,994	-18,188	-7,552	-17,578	-4,181	57,224	3,995	8,300	11,827	-38,760	66	60	-99	-112	11	1	9	741	-348	1	2	1	1
Net Income (Loss) Attributable to Parent
41,230	-192,626	3,331	-13,605	-14,301	-24,138	48,270	-21,048	33,824	-33,104	-15,992	-26,659	-26,741	-44,368	-12,894	-10,541	-20,917	-30,667	-11,785	-21,653	-11,633	94,623	6,454	12,746	17,939	41,801	6,514	478	-5,480	-3,702	-1,495	-15,780	-8,804	-13,836	-8,576	-5,679	98,817	1,891	4,126
Other comprehensive income:
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	-9	93	-	-187	97	-	-	-
Comprehensive income (loss)
41,230	-	3,331	-	-14,301	-	48,270	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,478	-15,789	-8,711	-	-8,763	-5,582	98,806	-	-
Basic net income (loss) per share (in dollars per share)
0.58	-2.69	0.05	-0.21	-0.22	-0.38	0.76	-0.33	0.53	-0.52	-0.25	-0.43	-0.43	-	-	-	-	-	-	-	-0.20	1.62	0.11	0.22	0.31	0.74	0.11	0.01	-0.10	-0.06	-0.03	-0.28	-0.16	-0.29	-0.15	-0.11	1.85	0.04	0.08
Diluted net income (loss) per share (in dollars per share)
0.58	-2.69	0.05	-0.21	-0.22	-0.23	0.65	-0.33	0.48	-0.52	-0.25	-0.43	-0.43	-	-	-	-	-	-	-	-0.20	1.43	0.11	0.21	0.30	0.73	0.11	0.01	-0.10	-0.06	-0.03	-0.28	-0.16	-0.25	-0.15	-0.11	1.77	0.04	0.08
Shares used in computing basic net income (loss) per share (in shares)
70,940	81,398	72,747	64,480	64,239	64,037	63,917	63,719	63,503	63,150	62,997	62,531	62,128	-	-	-	-	-	-	-	59,560	58,951	58,567	58,105	57,545	57,101	56,818	56,562	56,460	56,189	56,039	55,786	55,554	55,469	55,371	54,056	53,353	52,595	52,436
Shares used in computing diluted net income (loss) per share (in shares)
71,051	81,398	72,747	64,480	64,239	28,546	82,690	63,719	81,877	63,150	62,997	62,531	62,128	-	-	-	-	-	-	-	59,560	84,011	60,864	60,430	59,923	58,911	57,661	57,142	56,460	56,189	56,039	55,786	55,554	59,177	55,371	54,056	55,754	53,306	53,103
Basic and diluted net loss per share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.21	-0.17	-0.34	-	-0.20	-0.36	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares used in computing basic and diluted net loss per share (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	61,422	61,166	60,898	-	60,320	59,991	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product sales, net
Total revenues
9,252	28,917	27,502	25,937	26,450	29,339	29,435	26,838	44,354	94,159	95,204	100,232	90,285	123,675	110,303	116,517	104,571	111,059	104,726	94,295	31,670	33,884	30,584	28,245	21,506	18,789	16,278	14,106	9,129	12,489	9,684	3,201	2,109	509	9,205	16,153	15,311	9,829	11,657
Commercialization agreement, net
Total revenues
11,258	29,451	27,304	31,003	30,856	12,983	27,781	31,179	83,800	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalties and milestones
Total revenues
407	857	341	263	623	277	20,277	5,257	250	248	209	225	162	236	221	165	209	113	130	209	533	527	370	430	494	403	15,422	15,097	14,081	13,336	12,201	9,577	9,421	7,586	2,179	67	165	75	91
Gralise
Total revenues
547	-	-	-	13,278	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain (loss) on sale of assets
127,505	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NUCYNTA
Gain (loss) on sale of assets
-15,755	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-